Mirabella M, et al. - Researchers explored the safety and tolerability profile of dimethyl fumarate (DMF) in relapsing-remitting multiple sclerosis (RRMS). In addition, they sought individual variables associated with better clinical and radiological outcomes. Via analyzing the clinical and magnetic resonance imaging (MRI) data of patients with RRMS who started DMF between 2012 and 2017 in seven MS clinics in central Italy, they established the short-term safety, tolerability and effectiveness of DMF, supporting its use as an early treatment in MS.